Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

Clear Cell Tumor

Stomach Neoplasms

Ovarian Neoplasms, Carcinoma, Small Cell

Clear-cell metastatic renal cell carcinoma

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Lymphoma, Lymphoma, Non-Hodgkin

Head and Neck Neoplasms

Carcinoma, Hepatocellular

Muscle Invasive Bladder Urothelial Carcinoma

Stomach Neoplasms

Brain Neoplasms

Diabetes Mellitus

Triple Negative Breast Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Radiation Pneumonitis

Melanoma, Neoplasms

Oligometastatic Renal Cell Carcinoma

Hodgkin Disease

Lung Neoplasms, Neoplasms

Colorectal Cancer Metastatic

Hodgkin Disease

Hodgkin Disease

Neoplasm Metastasis

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Neoplasm Metastasis

Esophageal Squamous Cell Carcinoma

Carcinoma, Renal Cell, Kidney Neoplasms

Ovarian Neoplasms

Lung Neoplasms

Mesothelioma, Malignant

Vulvar Neoplasms, Neoplasms, Squamous Cell

Urologic Neoplasms

Colorectal Neoplasms

Kidney Neoplasms, Lung Neoplasms, Melanoma

Squamous Cell Carcinoma of Head and Neck, Deglutition Disorders, Head and Neck Neoplasms, Oropharyngeal Neoplasms

Carcinoma, Hepatocellular

Squamous Cell Carcinoma of Head and Neck

Fallopian Tube Neoplasms, Ovarian Neoplasms

Glioblastoma

Breast Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NSCLC With COPD

Carcinoma, Renal Cell, Melanoma

Esophageal Squamous Cell Carcinoma

Carcinoma, Non-Small-Cell Lung

Carcinoma, Renal Cell

Uterine Cervical Neoplasms

PD-1 Antibody

Clinical Trials

KeyPemls-004

PEACOCC

Pembrolizumab + Capecitabine／Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive

Pemb-HT

Pembrolizumab Plus Radiotherapy for Advanced Renal Cancer

Vaccination With Flt3L, Radiation, and Poly-ICLC

Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer

Longitudinal Immune-phenotyping of HCC Following MK-3475

Drug Screening Using IMD in Bladder Cancer

Gastric Cancer Organoids in the Screening of Neoadjuvant Drugs

TREATMENT

NSCLC

Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma

Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients

I-STOP

Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy

Neo Trio

PE-PE

PLIMATH

LUCACRIMUNO

POCHI

Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma

Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer

PRINCESS

Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001)

KEYPAD

MITO28MaNGOov4

Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901

MiST

Apollo

Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements

Pembro-SRT

PEMBROLA

Microbiome Immunotherapy Toxicity and Response Evaluation

QUASAR

Pembrolizumab Plus Y90 Radioembolization in HCC Subjects

PROBES

PROMPT

Neoadjuvant Chemoimmunotherapy in Recurrent Glioblastoma

A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer

Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation

Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma

Pembrolizumab as First-line Treatment for Advanced NSCLC Complicated With COPD

REFINE

Pembrolizumab Plus CRT Followed by Surgery in Upper ESCC

Luscid

CAPER

Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer

Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma